Active Pharmaceutical Ingredient (API) >>Rucaparib

Rucaparib is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 to treat ovarian cancer and metastatic castration-resistant prostate cancer. Rucaparib is a first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase-1 (PARP-1). 

Rucaparib inhibits the contraction of isolated vascular smooth muscle, including that from the tumours of cancer patients. It also reduces the migration of some cancer and normal cells in culture.

Rucaparib powder form is slightly soluble in water.

MF: C19H18FN3O
MW: 323.371 g/mol
CAS No.283173-50-2
 
Notice: If the compound involved in patent protection, do not use for commercial purposes, and only for the purpose of analysis and research experiments. If it’s sold to countries which constitute patent infringement, All the risks corresponding are unrelated to our company.

Rucaparib

Stay connected with our social network